Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | CHRNB2 | P17787 | 7/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 6/20 | 0.55 |
| ▸ | CHRNB4 | P30926 | 6/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9906306 | 1.00 | KMT2A (0.61) | KMT2ACHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL2301489 | 0.85 | KMT2A (0.70) | KMT2ACHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL2991760 | 0.84 | KMT2A (0.59) | KMT2ACHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL8313919 | 0.77 | — | — | |
| SCHEMBL2991035 | 0.76 | CHRNB2 (0.66) | KMT2ACHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL23861292 | 0.73 | KMT2A (0.84) | KMT2ANPSR1TSHRALDH1A1KDM4E | |
| SCHEMBL29043353 | 0.73 | KMT2A (0.84) | KMT2ANPSR1TSHRALDH1A1KDM4E | |
| SCHEMBL7765233 | 0.72 | KMT2A (0.49) | KMT2ANPSR1TSHRALDH1A1KDM4E | |
| SCHEMBL11015380 | 0.72 | KMT2A (0.81) | KMT2ANPSR1TSHRALDH1A1KDM4E | |
| SCHEMBL2731577 | 0.71 | KMT2A (0.52) | KMT2ANPSR1TSHRALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139857-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | Targacept Inc. (US) | 2010-01-06 | — | — | EP | claimed |
| WO-2008121686-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | TARGACEPT, INC. (US) | 2008-10-09 | — | — | WO | claimed |
| US-8198296-B2 | Sub-type selective azabicycloalkane derivatives | TARGACEPT, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100173968-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | TARGACEPT, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| EP-2139857-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | Targacept Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008121686-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | TARGACEPT, INC. (US) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173968-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | CHRNB2, CHRNB4, CHRNA4 | KMT2A 1990/4885CHRNB2 1/4885CHRNA4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.